Emerging strategies for lowering serum phosphorous in patients with end-stage renal disease.
Hyperphosphataemia is a major problem in patients with chronic kidney disease as it has been associated with increased morbidity and mortality. Over the last four decades, different modalities have been applied to treat hyperphosphataemia with varying degrees of success. Unfortunately, treatment strategies have led to unforeseen complications. These have prompted the development of new classes of medications with potentially better efficacy and few short-term and long-term side effects. This article reviews the causes, mechanism and management of hyperphosphataemia.
Ashfaq
Akhtar
A
Division of Kidney Division and Hypertension, North Shore University Hospital, 100 Community Drive, Great Neck, New York 11021, USA.
Gitman
Michael
M
Singhal
Pravin C
PC
D000328:Adult; D000069449:Cinacalcet; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000188:drug therapy / Q000628:therapy; D009281:Naphthalenes / Q000627:therapeutic use; D028044:Phosphate-Binding Proteins / Q000627:therapeutic use; D010758:Phosphorus / Q000097:blood*; D011073:Polyamines / Q000627:therapeutic use; D006435:Renal Dialysis; D000069603:Sevelamer
D009281:Naphthalenes; D028044:Phosphate-Binding Proteins; D011073:Polyamines; D010758:Phosphorus; D000069603:Sevelamer; D000069449:Cinacalcet